Press Releases Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
6.86 ^USD	-0.72%		+4.57%	+32.95%

May. 28	Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis	MT
May. 28	Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma	May. 29	AQ
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis	May. 28	AQ
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma	May. 28	AQ
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference	May. 07	AQ
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance	May. 02	AQ
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery	Apr. 29	AQ
Sight Sciences : SGHT Proxy - Apr'24	Apr. 26	PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024	Apr. 18	AQ
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma	Apr. 10	GL
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	Apr. 03	AQ
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	Apr. 02	AQ
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference	Mar. 26	AQ
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance	Mar. 07	AQ
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024	Feb. 22	AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting	Feb. 15	AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting	Feb. 14	AQ
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital	Jan. 23	AQ
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights	Jan. 08	AQ
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors	Dec. 28	AQ
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Press Releases

Filters